DE3641491A1 - Arzneimittel mit antitumorwirkung - Google Patents

Arzneimittel mit antitumorwirkung

Info

Publication number
DE3641491A1
DE3641491A1 DE19863641491 DE3641491A DE3641491A1 DE 3641491 A1 DE3641491 A1 DE 3641491A1 DE 19863641491 DE19863641491 DE 19863641491 DE 3641491 A DE3641491 A DE 3641491A DE 3641491 A1 DE3641491 A1 DE 3641491A1
Authority
DE
Germany
Prior art keywords
hexadecylphosphocholine
weight
mixture
optionally
alkylglycerol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19863641491
Other languages
German (de)
English (en)
Inventor
Hansjoerg Eibl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority to DE19863641491 priority Critical patent/DE3641491A1/de
Publication of DE3641491A1 publication Critical patent/DE3641491A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electrically Operated Instructional Devices (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DE19863641491 1985-12-04 1986-12-04 Arzneimittel mit antitumorwirkung Withdrawn DE3641491A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19863641491 DE3641491A1 (de) 1985-12-04 1986-12-04 Arzneimittel mit antitumorwirkung

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE3542893 1985-12-04
DE3606631 1986-02-28
DE19863641491 DE3641491A1 (de) 1985-12-04 1986-12-04 Arzneimittel mit antitumorwirkung

Publications (1)

Publication Number Publication Date
DE3641491A1 true DE3641491A1 (de) 1987-09-17

Family

ID=25838509

Family Applications (4)

Application Number Title Priority Date Filing Date
DE19863641491 Withdrawn DE3641491A1 (de) 1985-12-04 1986-12-04 Arzneimittel mit antitumorwirkung
DE19863641379 Withdrawn DE3641379A1 (de) 1985-12-04 1986-12-04 Arzneimittel
DE8686906829T Expired - Lifetime DE3679908D1 (de) 1985-12-04 1986-12-04 Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.
DE19375061C Active DE19375061I2 (de) 1985-12-04 1986-12-04 Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.

Family Applications After (3)

Application Number Title Priority Date Filing Date
DE19863641379 Withdrawn DE3641379A1 (de) 1985-12-04 1986-12-04 Arzneimittel
DE8686906829T Expired - Lifetime DE3679908D1 (de) 1985-12-04 1986-12-04 Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.
DE19375061C Active DE19375061I2 (de) 1985-12-04 1986-12-04 Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.

Country Status (15)

Country Link
US (2) US4837023A (enEXAMPLES)
EP (4) EP0230575A3 (enEXAMPLES)
JP (2) JPH0637393B2 (enEXAMPLES)
AT (2) ATE64529T1 (enEXAMPLES)
CA (2) CA1338627C (enEXAMPLES)
DE (4) DE3641491A1 (enEXAMPLES)
DK (2) DK172954B1 (enEXAMPLES)
ES (2) ES2032755T3 (enEXAMPLES)
FI (2) FI873363A0 (enEXAMPLES)
GR (2) GR3002487T3 (enEXAMPLES)
HU (2) HU203201B (enEXAMPLES)
IE (2) IE59778B1 (enEXAMPLES)
NO (2) NO175620C (enEXAMPLES)
PT (2) PT83872B (enEXAMPLES)
WO (2) WO1987003480A2 (enEXAMPLES)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916884A (en) * 1985-12-04 1999-06-29 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Compositions containing a mixture of phosphorus compounds and alkylglycerols
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
US5182271A (en) * 1989-08-10 1993-01-26 Sandoz Ltd. Thioether, keto-ester and alkyl phospholipids useful in treating multiple sclerosis
DK0412941T3 (da) * 1989-08-10 1996-06-24 Sandoz Ag Phospholipider til behandling af dissemineret sklerose
EP0916343A1 (de) * 1989-09-27 1999-05-19 ASTA Medica Aktiengesellschaft Verwendung von Alkylphosphorsäure-Verbindungen zur Bekämpfung von Psoriasis-Erkrankungen
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
DE4111105A1 (de) * 1991-04-05 1992-10-08 Max Planck Gesellschaft Neue erucyl-, brassidyl- und nervonylderivate
US5506217A (en) * 1991-04-25 1996-04-09 The University Of British Columbia Phosphonates as anti-cancer agents
US5369097A (en) * 1991-04-25 1994-11-29 The University Of British Columbia Phosphonates as anti-cancer agents
EP0521297B1 (de) * 1991-07-04 1997-09-17 ASTA Medica Aktiengesellschaft Verfahren zur Herstellung von Alkylphosphocholinen und Reinherstellung derselben
US6254879B1 (en) 1991-09-27 2001-07-03 Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. Methods of treating protozoal diseases
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
US5298655A (en) * 1991-09-27 1994-03-29 Merck & Co., Inc. Farnesyl pyrophosphate analogs
US6172050B1 (en) 1992-07-11 2001-01-09 Asta Medica Aktiengesellschaft Phospholipid derivatives
DE4222910A1 (de) * 1992-07-11 1994-01-13 Asta Medica Ag Neue Phospholipidderivate
DE4235911A1 (de) * 1992-10-23 1994-04-28 Asta Medica Ag Stabilisierte Hexadecylphosphocholinlösungen in Glycerinalkylethern
EP0702556B1 (en) * 1993-06-10 2002-10-23 Wake Forest University (phospho)lipids for combatting hepatitis b virus infection
NZ273258A (en) 1993-09-09 2000-01-28 Lorus Therapeutics Inc Immunomodulator composition with components less than 3000 D that are extractable from bile, stimulate monocytes and macrophages and modulate TNF
US6551623B1 (en) 1993-09-09 2003-04-22 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US7135584B2 (en) * 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
EP0781138B1 (en) * 1994-08-29 2008-05-21 Wake Forest University Lipid analogs for treating viral infections
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
AU1573495A (en) * 1995-02-10 1996-08-27 University Of British Columbia, The {4-hexadecyl-3-methoxy-butyl} phosphonic acid and its protienconjugates useful as anti-cancer agents
CN1182368A (zh) 1995-03-16 1998-05-20 伊姆特克药物公司 来源于胆汁的治疗免疫系统紊乱的免疫调节组合物
KR100499190B1 (ko) * 1996-03-29 2006-04-17 교와 핫꼬 고교 가부시끼가이샤 육모제
US20040101569A1 (en) * 1996-05-16 2004-05-27 Lorus Therapeutics Inc. Immunomodulating compositions from bile
US6121245A (en) * 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
SE9701912D0 (sv) * 1997-05-22 1997-05-22 Interhealth Ab Pharmaceutical composition and use thereof
US7582678B2 (en) * 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
UA68372C2 (en) * 1998-01-22 2004-08-16 Solid pharmaceutical composition containing hexadecylphosphocholine (miltefosine) for oral administration in treatment of leishmaniasis
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
IL137672A0 (en) 2000-08-03 2001-10-31 Dpharm Ltd Derivatives of branched-chain lipophilic molecules and uses thereof
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
EP1397326A2 (en) * 2001-05-29 2004-03-17 Koninklijke Philips Electronics N.V. Metal-ceramic bond
KR100871648B1 (ko) * 2001-08-31 2008-12-03 톰슨 라이센싱 조건부 액세스 시스템을 구현하는 방법, 컨텐트를 전송하는 방법 및 그 장치 및 컨텐트를 수신하고 처리하는 방법 및 그 장치
WO2003090757A1 (en) * 2002-04-26 2003-11-06 Rudolf Perl Pharmaceutical compositions of phospholipid derivatives
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
WO2007071658A2 (en) 2005-12-19 2007-06-28 Æterna Zentaris Gmbh Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof
US8637688B2 (en) * 2006-12-20 2014-01-28 Julia Diederichs Topical dosage form comprising tri-substituted glycerol compounds
JP2011057647A (ja) * 2009-09-14 2011-03-24 Adeka Corp 化粧料
MX367850B (es) 2011-06-24 2019-09-09 Gri Bio Inc Prevención y tratamiento de condiciones inflamatorias.
CN102491994B (zh) * 2011-12-07 2014-10-15 宁波九胜创新医药科技有限公司 一种胆碱磷酸烷基酯的制备方法
KR102665487B1 (ko) * 2014-12-09 2024-05-10 쥐알아이 바이오,아이엔씨. 염증 질환의 예방 및 치료

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3225227A1 (de) * 1982-07-06 1984-01-12 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Derivate des n.n-bis-(2-chlor-aethyl)-phosphorsaeureamids
JPS5984824A (ja) * 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
US4690935A (en) * 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds
JPS60184092A (ja) 1984-03-01 1985-09-19 Kao Corp リン酸エステルおよびその製法

Also Published As

Publication number Publication date
WO1987003480A3 (en) 1988-02-25
PT83872B (pt) 1989-01-17
IE59777B1 (en) 1994-04-06
HU203201B (en) 1991-06-28
WO1987003478A2 (en) 1987-06-18
EP0225608A3 (de) 1987-10-28
NO174877C (no) 1994-07-27
NO175620C (no) 1994-11-09
DE19375061I2 (de) 2008-11-20
JPH0859677A (ja) 1996-03-05
FI873364A0 (fi) 1987-08-03
EP0248047A1 (de) 1987-12-09
IE59778B1 (en) 1994-04-06
JPH0637393B2 (ja) 1994-05-18
ATE75608T1 (de) 1992-05-15
DK172954B1 (da) 1999-10-18
NO873244L (no) 1987-10-01
GR3005168T3 (enEXAMPLES) 1993-05-24
EP0248047B1 (de) 1991-06-19
NO174877B (no) 1994-04-18
DK398587D0 (da) 1987-07-30
PT83873B (pt) 1989-01-17
ATE64529T1 (de) 1991-07-15
EP0225608A2 (de) 1987-06-16
CA1338627C (en) 1996-10-01
HUT44441A (en) 1988-03-28
IE863177L (en) 1987-06-04
EP0230575A3 (de) 1987-12-02
NO873244D0 (no) 1987-08-03
CA1280369C (en) 1991-02-19
DK393187D0 (da) 1987-07-28
WO1987003480A2 (en) 1987-06-18
PT83873A (de) 1987-01-01
FI873363A7 (fi) 1987-08-03
ES2032755T3 (es) 1993-03-01
FI873364A7 (fi) 1987-08-03
HU208143B (en) 1993-08-30
JP2857084B2 (ja) 1999-02-10
US5049552A (en) 1991-09-17
NO873243D0 (no) 1987-08-03
GR3002487T3 (en) 1992-12-30
HUT44431A (en) 1988-03-28
WO1987003478A3 (en) 1987-09-24
US4837023A (en) 1989-06-06
JPS63501719A (ja) 1988-07-14
DE3641379A1 (de) 1987-09-03
NO175620B (enEXAMPLES) 1994-08-01
IE863176L (en) 1987-06-04
EP0248062A1 (de) 1987-12-09
DK393187A (da) 1987-07-28
NO873243L (no) 1987-10-02
ES2038215T3 (es) 1993-07-16
FI873363L (fi) 1987-08-03
EP0230575A2 (de) 1987-08-05
PT83872A (de) 1987-01-01
DK398587A (da) 1987-07-30
FI873363A0 (fi) 1987-08-03
DE3679908D1 (de) 1991-07-25
EP0248062B1 (de) 1992-05-06

Similar Documents

Publication Publication Date Title
EP0248047B1 (de) Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung
DE69925407T2 (de) Präparat zur perkutan Verabreichung enthaltend Donepezil Hydrochlorid
DE3650488T2 (de) Verwendung eines Tetrahydrocarbazolonderivates zur Herstellung von Arzneimitteln
EP0534445B1 (de) Verfahren zur Herstellung eines Arzneimittels zur oralen oder topischen Verabreichung bei der Behandlung von Leishmaniasis
EP0241809A1 (de) Synergistische Kombination von Amantadin und Selegilin
EP0501205B1 (de) Antiphlogistisches Mittel
DE69924004T2 (de) Verabreichungssystem für wasserunlösliche arzneistoffe
EP0871437B1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
CH642261A5 (de) Arzneipraeparat auf der basis eines salzes der acetylsalicylsaeure und einer basischen aminosaeure und verfahren zu seiner herstellung.
EP0147735B1 (de) Pharmazeutisches Präparat zur therapeutischen Behandlung von rheumatischen Erkrankungen
DE2926463C2 (enEXAMPLES)
DE69115528T2 (de) Neue pharmazeutische Verwendungen von Forskolin-Derivaten
DE4029747C2 (de) Verwendung von Hexadecylphosphocholin zur Behandlung von Psoriasis-Erkrankungen
DE69023045T2 (de) Carboxamidderivate.
DD242349A5 (de) Verfahren zur herstellung einer synergistischen kombination von flupirtin und 4-acetamido-phenol
EP1524273A1 (de) Verfahren zur Herstellung von trans- oder cis-Diammoniumdichlorodihydroxoplatin (IV)-Salzen und -Derivaten und ihre Verwendung zur Herstellung von pharmazeutischen Wirkstoffen
DD281961A5 (de) Verfahren zur herstellung eines antitumorwirksamen arzneimittels
DE3419425A1 (de) Verwendung von d-3-acetoxy-cis-2,3-dihydro-5-(2-(dimethylamino)ethyl)-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5h)-on als arzneimittel zur bekaempfung der hypolipidaemie
DE69426317T2 (de) Verwendung von Beta-Naphthochinonderivaten zur Hemmung von Blutplättchen-Aggregation
DE3406837C2 (enEXAMPLES)
DE2515142B2 (de) Oral verabfolgbare mittel zur senkung des lipid- und cholesterin- spiegels
CH688398A5 (de) Verwendung von 2-Beta-D-Ribofuranosylthiazol-4-carboxamid und verwandter Verbindungen fuer die Erzeugung von Medikamenten mit Antitumor-Aktivitaet.
DE2124249C3 (de) Trans-2-chlor-l 1 -(3-piperazinyl- propyliden)-6Hdibenz- [b,e] -oxepin, Verfahren zu seiner Herstellung und pharmazeutisches Präparat
EP0287014A2 (de) Cholesteryl-phosphorylcholin zur Senkung des Cholesterinspiegels
DE3033814A1 (de) Arzneimittelzubereitung von n(pfeil hoch)4-acylcytosinarabinosiden

Legal Events

Date Code Title Description
8141 Disposal/no request for examination